Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Vespula vulgaris venom protein is a standardized allergenic extract derived from the venom of the common wasp (*Vespula vulgaris*), a species of yellow jacket. It is primarily utilized as a diagnostic tool in skin testing to identify patients with Hymenoptera venom hypersensitivity and as an active ingredient in venom immunotherapy (VIT) to induce immunological tolerance. The venom contains several potent allergenic proteins, most notably phospholipase A1 (Ves v 1), hyaluronidase (Ves v 2), and antigen 5 (Ves v 5). In diagnostic applications, the extract cross-links IgE antibodies on the surface of mast cells and basophils, triggering a wheal-and-flare reaction. In therapeutic settings, repeated administration of increasing doses of the venom protein induces a shift from a Th2-mediated IgE response toward a Th1-mediated response and the production of venom-specific IgG4 blocking antibodies, which prevent systemic anaphylactic reactions upon future stings.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on vespula vulgaris venom protein.